GlassScriptPhysician profile
Avi Bitterman
NPI 1851755490
$2,790.12
in general payments reported to CMS, 2019-2025
10 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,911 · 2021: $268 · 2022: $150 · 2023: $288 · 2024: $38.64 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,911.27 | 2020 | |
| Janssen Scientific Affairs, LLC | $387.06 | 2021-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $203.46 | 2022-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $57.82 | 2021-2022 | |
| Janssen Biotech, INC. | $57.08 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $50.59 | 2023 | Sotyktu |
| Genzyme Corporation | $38.64 | 2024 | |
| Leo Pharma INC. | $38.25 | 2022 | |
| Galderma Laboratories, L.P. | $26.77 | 2025 | Nemluvio |
| Lilly USA, LLC | $19.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Bitterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.